Alto Neuroscience
ANRO
80 hedge funds and large institutions have $38.1M invested in Alto Neuroscience in 2025 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 21 increasing their positions, 23 reducing their positions, and 23 closing their positions.
9% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 23
4% less funds holding
Funds holding: 83 → 80 (-3)
13% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 23
13.12% less ownership
Funds ownership: 77.01% → 63.89% (-13%)
15% less capital invested
Capital invested by funds: $45M → $38.1M (-$6.98M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
75% less call options, than puts
Call options by funds: $11K | Put options by funds: $44K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$682K |
| 2 |
PLC
Peapod Lane Capital
Bedford Hills,
New York
|
+$664K |
| 3 |
Jane Street
New York
|
+$259K |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$213K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$201K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.01M |
| 2 |
BlackRock
New York
|
-$2.14M |
| 3 |
AIC
AWM Investment Company
New York
|
-$1.48M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.19M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$777K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Simplex Trading
Chicago,
Illinois
| – | -$1.39K | -584 | Closed |
|
|
PWA
102
Physician Wealth Advisors
Midvale,
Utah
| – | -$815 | -377 | Closed |
|
|
SCM
103
Sterling Capital Management
Charlotte,
North Carolina
| – | -$348 | -161 | Closed |
|
ANRO Hedge Fund Activity: Q2 2025 in Review
80 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Alto Neuroscience (ANRO) for Q2 2025, worth a combined $38.1M — down 15% from $45M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of ANRO and 20 opened new positions — a net loss of 3 holders — while 23 trimmed existing stakes and 21 added.
The largest buyer was Millennium Management, adding an estimated $682K. The largest seller was Fidelity Investments, cutting an estimated $3.01M.
- 80 institutional investors held Alto Neuroscience (ANRO) as of Q2 2025, down from 83 in Q1 2025.
- Funds reported $38.1M of Alto Neuroscience stock for Q2 2025, down 15% quarter-over-quarter.
- 20 funds opened new Alto Neuroscience positions in Q2 2025 and 23 closed out, a net change of -3 holders.
- The largest Alto Neuroscience buyer in Q2 2025 was Millennium Management, an estimated $682K added.
- The largest Alto Neuroscience seller in Q2 2025 was Fidelity Investments, an estimated $3.01M sold.
Based on aggregated 13F filings for Q2 2025.